|2.||Laryngeal Neoplasms (Laryngeal Cancer)
|4.||Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
|1.||Bay, Boon-Huat: 11 articles (02/2009 - 07/2002)|
|2.||Chan, Anthony T C: 7 articles (11/2013 - 04/2007)|
|3.||Olivo, Malini: 7 articles (12/2006 - 07/2002)|
|4.||Marsh, Gary M: 6 articles (01/2014 - 07/2002)|
|5.||Hui, Edwin P: 6 articles (11/2013 - 04/2007)|
|6.||Luk, W S: 5 articles (05/2015 - 01/2014)|
|7.||Ng, Shamay S M: 5 articles (05/2015 - 01/2014)|
|8.||Fong, Shirley S M: 5 articles (05/2015 - 01/2014)|
|9.||Pan, Jianji: 5 articles (01/2014 - 11/2008)|
|10.||Youk, Ada O: 5 articles (11/2010 - 07/2002)|
|1.||Cisplatin (Platino)FDA LinkGeneric
05/01/2014 - "We conducted this study to assess the value of excision repair cross-complementation group 1 (ERCC1) protein expression in predicting the clinical outcome of patients with locally advanced nasopharyngeal cancer who were treated with cisplatin-based concurrent chemoradiotherapy. "
02/01/2013 - "The purpose of this study was to determine the effect of all-trans retinoid acid (ATRA) on two nasopharyngeal cancer (NPC) cell lines and to evaluate the synergistic effect of ATRA used in combination with cisplatin, a standard chemotherapeutic agent for NPC. "
10/01/2007 - "Treatment results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil--a phase II study."
01/01/2001 - "In this study, we studied two nasopharyngeal cancer cell lines with a four-fold difference in sensitivity to cisplatin. "
06/01/1997 - "Requiring institutions to inform participants who have completed therapy on SWOG-8892 (RT +/- cisplatin for nasopharyngeal cancer) about early study closure: right idea, wrong patients."
|2.||Fluorouracil (Carac)FDA LinkGeneric
09/01/2012 - "These results suggest that combinational therapy of overexpressed hTERTC27, which is driven by the 5-FU-activated Egr-1 promoter, and 5-FU may provide a novel approach to treat nasopharyngeal cancer."
12/01/2001 - "Alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil: a preliminary report of phase II study."
08/01/2003 - "Concurrent chemoradiotherapy with daily low dose intra-arterial cisplatin plus 5-fluorouracil for stage IV nasopharyngeal cancer."
12/01/2001 - "Therapeutic results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil: its usefulness and controversial points."
10/01/2010 - "To assess whether the benefits of adding cisplatin (CDDP) concurrent with radiotherapy, followed by adjuvant CDDP and fluorouracil, justifies the toxicity cost for nasopharyngeal cancer (NPC) using the quality-adjusted time without symptoms or toxicity (Q-TWiST) approach. "
|3.||docetaxel (Taxotere)FDA Link
06/01/2011 - "This study suggests that the cooperative influence of functional polymorphisms in SLCO1B3 and ABCB1 genes may be responsible for the interindividual variability in docetaxel disposition in Asian nasopharyngeal cancer patients."
04/01/2012 - "Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients."
11/01/2012 - "A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01)."
02/01/2014 - "This exploratory study was aimed at elucidating the pharmacogenetics of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) and their implications on docetaxel pharmacokinetics and pharmacodynamics in local Chinese nasopharyngeal cancer patients. "
02/01/2014 - "Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients."
|4.||DNA (Deoxyribonucleic Acid)IBA
01/01/2000 - "Our report is the first study investigating the expression of the c-erbB-2 gene in nasopharyngeal cancer at the DNA level."
06/01/2014 - "Elevated levels of circulating cell-free Epstein-Barr virus (EBV) DNA have been detected in plasma and serum samples from nasopharyngeal cancer (NPC) patients by quantitative real time PCR (qPCR) test. "
01/01/2014 - "Identification of novel tumor suppressor genes down-regulated in recurrent nasopharyngeal cancer by DNA microarray."
03/01/2013 - "Using lipid-mediated DNA transfection technique, the low metastatic nasopharyngeal cancer cells 6-10B were transfected in vitro with plasmid which contained CD44 gene, and then new nasopharyngeal cancer cells were obtained. "
01/01/2012 - "The aim of this prospective study was to evaluate the relationship between viral Epstein-Barr DNA copy numbers in plasma and the response rate, progression-free survival and overall survival in a cohort of Western patients with stage IIb-IVb nasopharyngeal cancer. "
06/01/2001 - "The multi-stage cell model of the nasopharyngeal carcinoma development in vitro by Epstein-Barr virus transformation is beneficial for the elucidation of the mechanism of nasopharyngeal cancer. "
11/01/2015 - "Although environmental and genetic factors are known for nasopharyngeal carcinoma, the present study is an attempt to provide a hypothesis behind the development of NPC with regards to the anatomical factor, the hypothesis being that patients with a deeper palatal vault tend to have a higher risk of developing nasopharyngeal cancers. "
08/01/2014 - "Our previous study identified that the CD44+ nasopharyngeal cancer (NPC) cells may be assumed as one of markers of nasopharyngeal carcinoma cancer stem cell-like cells (CSC-LCs) and Bmi-1 is overexpressed in CD44+ NPC. "
04/01/2014 - "Although there are reported in literature series of nasopharyngeal cancer metastasizing to bone, we did not find previously published report of a nasopharyngeal carcinoma metastasizing only to a rib. "
11/01/2010 - "Nasopharyngeal carcinoma (NPC) is the most common nasopharyngeal neoplasm and has a high propensity for developing regional neck adenopathy. "
10/15/1999 - "The motivation for this problem came from the very positive results and early termination of a randomized clinical trial for nasopharyngeal cancer co-ordinated by the Southwest Oncology Group."
03/01/1961 - "Seven of twenty-two patients treated with intracavitary Co(60) therapy for nasopharyngeal neoplasms remained controlled for more than five years.No"
08/01/2007 - "Further updates of the NCI formaldehyde cohort study should include co-exposure data on silver smithing and other metal work for all study plants to help explain the unique findings for nasopharyngeal cancer in Plant 1 compared with the other nine plants."
05/01/2014 - "To co-deliver hydrophobic drug and functional gene efficiently into tumor cells, a star-shaped copolymer (PP-PLLD-Arg) with a photochemical internalization effect consisting of a porphyrin (PP) core and arginine-functionalized poly(L-lysine) dendron (PLLD-Arg) arms has been designed, and used to co-deliver docetaxel (DOC) and MMP-9 shRNA plasmid for nasopharyngeal cancer therapy. "
12/01/2013 - "The authors studied the efficacy of neoadjuvant chemotherapy, consisting of a taxane, cisplatin, and 5-fluorouracil (5-FU) (the TPF regimen) followed by concurrent chemoradiation, in 2 separately designed and synchronously executed phase 2 trials for stage III and IVA/IVB nasopharyngeal cancer (NPC). "
01/01/2010 - "Targeted gene therapy of nasopharyngeal cancer in vitro and in vivo by enhanced thymidine kinase expression driven by human TERT promoter and CMV enhancer."
10/01/2005 - "Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase."
07/16/2007 - "To enhance the efficacy of ganciclovir/herpes simplex virus thymidine kinase (GCV/HSV-TK) suicide gene therapy for nasopharyngeal cancer KB, we developed long-circulating liposome-encapsulated GCV, and evaluated cytotoxicity in vitro and in vivo. "
10/01/2005 - "For targeted gene delivery to human prostate cancer LNCaP and PC-3 cells and nasopharyngeal cancer KB cells, we developed a folate-linked nanoparticle (NP-F), and evaluated the potential of NP-F-mediated suicide gene therapy in the cells and xenografts with herpes simplex virus thymidine kinase (HSV-tk) and connexin 43 (Cx43). "
|9.||Cyclin-Dependent Kinase Inhibitor p16IBA
01/01/2015 - "We here evaluated p16 INK4A as a prognostic marker of treatment response and survival in our SCCHN patients with laryngeal, hypopharyngeal or nasopharyngeal cancers. "
01/01/2015 - "P16 INK4A status predicts better outcome in laryngeal, hypopharyngeal or nasopharyngeal cancer cases treated with surgery plus adjuvant radiochemotherapy as well as with definitive radiation therapy and/or chemotherapy."
|10.||Ganciclovir (Cytovene)FDA LinkGeneric
01/01/2006 - "A randomized trial has demonstrated that concurrent chemoradiotherapy (CRT) is superior to radiotherapy (RT) alone in locally advanced nasopharyngeal cancer (NPC). "
03/01/2002 - "Radiotherapy is the mainstay of treatment for early nasopharyngeal cancer, but combination chemoradiotherapy is becoming more common for patients with advanced disease since the Intergroup trial 0099 demonstrated improved progression-free survival and overall survival for chemoradiotherapy. "
04/01/1998 - "We conclude that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to PFS and overall survival."
12/01/2012 - "Primary radiotherapy has been the mainstay of treatment of patients with nondisseminated nasopharyngeal cancer (NPC). "
12/01/2005 - "Nasopharyngectomy is safe and effective in the treatment of recurrent nasopharyngeal cancer even after multiple courses of radiotherapy."
|2.||Drug Therapy (Chemotherapy)
10/01/2003 - "High dose radiation therapy, coupled with concurrent chemotherapy, was judged a highly effective treatment for locally advanced nasopharynx cancers."
09/01/2014 - "Prolonged complete remission after induction chemotherapy followed by chemoradiation with tomotherapy in metastatic nasopharyngeal cancer."
12/01/2004 - "While reirradiation without chemotherapy appears to be effective in recurrent nasopharynx cancer cases, the use of concomitant chemotherapy with reirradiation appears to offer improved outcomes based on phase I/II data in other head and neck sites. "
12/01/2012 - "Intensity-modulated radiation therapy with simultaneous integrated boost with concurrent chemotherapy is a safe and effective treatment modality for nasopharyngeal cancer. "
09/01/2009 - "Our aim was to evaluate the feasibility and efficacy of intensity-modulated radiation therapy (IMRT) with simultaneous integrated boost (SIB) technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal cancer (NPC). "
09/01/1991 - "In the treatment of nasopharyngeal cancer, adjuvant chemotherapy after therapeutic dose of irradiation indicates a better survival rate than radiation alone, and in advanced nasopharyngeal cancer, a wide resection is effective for cure. "
02/01/1996 - "[Efficacy of adjuvant chemotherapy in nasopharyngeal cancer]."
01/01/2013 - "Concurrent chemoradiation without the addition of adjuvant chemotherapy cycles using IMRT with an integrated boost concept yielded good disease control and overall survival in patients suffering from primary nasopharyngeal cancer with acceptable acute side effects and limited rates of late toxicity."
01/01/2005 - "[Concomitant radiochemotherapy followed by adjuvant chemotherapy in patients with poorly differentiated nasopharyngeal cancer; tolerance and early results of treatment]."
10/01/2003 - "Does the Addition of Adjuvant Chemotherapy to Concurrent Chemoradiotherapy Improve the Survival of Patients with Locally Advanced Nasopharyngeal Cancer?"
|4.||Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
01/01/2013 - "Replanning in intensity-modulated radiotherapy (IMRT) has been reported to improve quality of life and loco-regional control in patients with nasopharyngeal cancer (NPC). "
01/01/2015 - "Thirty nasopharyngeal cancer patients scheduled to undergo intensity-modulated radiotherapy (IMRT) were prospectively enrolled in the study. "
10/01/2014 - "The aim of this study was to prospectively evaluate the cognitive function, depression, anxiety, and sleep quality in patients with nasopharyngeal cancer (NPC) before and after intensity-modulated radiotherapy (IMRT). "
12/01/2013 - "The objective of the study was to evaluate locoregional control after intensity-modulated radiotherapy for nasopharyngeal cancer using a target definition along with anatomical boundaries. "
02/01/2010 - "The aim of this study was to analyze the clinical results of our adaptive radiation therapy scheme of a two-step intensity-modulated radiotherapy (IMRT) method for nasopharyngeal cancer (NPC) at Kinki University Hospital. "
07/15/2000 - "Interstitial afterloading brachytherapy can provide effective treatment for nasopharyngeal cancers, especially for locally persistent/recurrent and locally extensive lesions."
03/01/2015 - "HDR brachytherapy is one of the commonest methods of nasopharyngeal cancer treatment. "
03/01/2015 - "Accuracy Evaluation of Oncentra™ TPS in HDR Brachytherapy of Nasopharynx Cancer Using EGSnrc Monte Carlo Code."
01/01/2013 - "Local control in advanced cancer of the nasopharynx: is a boost dose by endocavitary brachytherapy of prognostic significance?"
11/01/2008 - "[Brachytherapy for head and neck cancers (nasopharynx excluded)]."